Rucker JJ

Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial.

Rucker JJ, Mantingh T, Kerr-Gaffney J +26

Psychological change processes in alcohol use disorder: A qualitative study of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) with cognitive behavioural therapy.

Seynaeve M, Dunbar F, Ermakova AO +4

ArticlePsychedelics

Characterising the clinical associations of hallucinogen persisting perception disorder: a retrospective cohort study.

Butler M, Moore E, Rucker JJ +6

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-<i>N,N</i>-dimethyltryptamine) in patients with treatment-resistant depression.

Roberts C, Seynaeve M, Ermakova AO +5

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial.

Marsden J, Kelleher M, Dunbar F +8

Europe PMC2025

Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial.

McGowan NM, Rucker JJ, Yehuda R +6

Psychedelic-related deaths in England, Wales and Northern Ireland (1997-2022).

Kopra EI, Penttinen J, Rucker JJ +1

Europe PMC2025

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-<i>N,N</i>-dimethyltryptamine benzoate) in healthy participants.

Rucker JJ, Roberts C, Seynaeve M +6

Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.

Haniff ZR, Bocharova M, Mantingh T +7

Evidence versus expectancy: the development of psilocybin therapy.

Rucker JJ

The development of psilocybin therapy for treatment-resistant depression: an update.

Borissova A, Rucker JJ

Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions.

Modlin NL, Creed M, Sarang M +3

Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis.

Ko K, Carter B, Cleare AJ +1

Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020.

Kopra EI, Ferris JA, Winstock AR +3

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation.

Modlin NL, Miller TM, Rucker JJ +4

Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.

Ko K, Kopra EI, Cleare AJ +1

Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review.

Ko K, Knight G, Rucker JJ +1

ArticleLSD

Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD).

Kopra EI, Ferris JA, Rucker JJ +4

Postpartum depression: A role for psychedelics?

Jairaj C, Rucker JJ

Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.

Kopra EI, Ferris JA, Winstock AR +2

The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.

Rucker JJ, Marwood L, Ajantaival RJ +12

Psilocybin: From Serendipity to Credibility?

Rucker JJ, Young AH

Europe PMC2021